Quantum Computing in the Pharmaceutical Industry
The past two years have seen rapid advances in building scalable quantum computers. It is now widely expected that a device that cannot be simulated by any classical computer (so-called ‘quantum computational supremacy’) will emerge in 2019. The prospect of a relatively near-term device capable of a quantum advantage has sparked a huge amount of excitement in academia, industry and government funding.
A recent report from Boston Consulting Group estimates that the market potential of quantum computing in pharmaceuticals could be $15B-$30B within 10 years. The central mechanism being the accurate simulation of proteins in order to find binding sites for new drugs and the impact this has on higher success rates at later stage trials.
The workshop brings together experts in quantum computing, the pharmaceutical industry and (classical) computational methods to discuss if this is realistic and explore other potential applications in the pharmaceutical industry.
Agenda to follow, sessions to include talks on:
- Quantum computing landscape
- Simulation state-of-the-art on classical architectures
- The drug discovery pipeline
- Panel discussion
- UK funding landscape for quantum